Taiwan Brings 22 Biotech and Pharma Firms to CPHI Milan 2026
Taiwan has gathered 22 biotech and pharmaceutical companies in a Taiwan Pharma Pavilion at CPHI Milan 2026, positioning itself as an integrated partner for drugmakers rethinking their supply chains. The pavilion is supported by Taiwan's Ministry of Economic Affairs (MOEA) and organized by the Industrial Technology Research Institute (ITRI).
- Taiwan has brought 22 biotech and pharma companies to CPHI Milan 2026 under the Taiwan Pharma Pavilion.
- The pavilion is supported by the MOEA and organized by ITRI.
- According to the organizers, over 170 Taiwanese manufacturers operate under PIC/S GMP standards and the region exports more than 90% of its APIs.
- Focus areas are AI drug discovery, APIs and CDMO services, and innovative therapeutics and advanced formulations.
- Dr. Maggie Lu of ITRI will give the opening remarks at the CPHI Leadership Summit.
A pavilion built around supply chain reliability
According to the announcement, the global pharmaceutical supply chain is restructuring quickly, and drugmakers are putting more weight on supply reliability, manufacturing quality and diversified partnerships. The Taiwan Pharma Pavilion is presented as a response to those demands, combining the region's advanced technology sector with pharmaceutical manufacturing.
The organizers cite several figures to support the case. Over 170 pharmaceutical manufacturers in Taiwan currently operate under stringent PIC/S GMP standards. The region exports more than 90% of its active pharmaceutical ingredients (APIs), and its finished pharmaceutical products consistently reach highly regulated markets, including Japan and the United States. These are claims made by the organizers.
Three areas of collaboration
Rather than competing solely on volume, the pavilion highlights collaboration in three core areas:
- AI-Driven Drug Discovery and Preclinical Research: Drawing on Taiwan's ICT strengths, participating companies show AI platforms and R&D tools meant to speed up target identification, drug screening and preclinical validation.
- APIs and CDMO Services: Taiwanese manufacturers offer raw material supply, scalable process development and flexible contract manufacturing backed by international certifications, aimed at companies seeking supply chain diversification.
- Innovative Therapeutics and Advanced Formulations: Capabilities cover novel drugs, 505(b)(2) high-barrier generics and advanced drug delivery technologies, with openings for co-development, technology licensing and global market expansion.
Executive-level presence
Taiwan's involvement goes beyond the exhibition floor. Dr. Maggie Lu, ITRI's Vice President and General Director of Biomedical Technology and Device Research Laboratories, has been invited to give the opening remarks at the CPHI Leadership Summit. According to the announcement, the platform lets Taiwan engage directly with senior executives from companies such as Boehringer Ingelheim, FUJIFILM and Lonza.
Lu said: "The global pharmaceutical supply chain is undergoing a strategic realignment." She added that global pharmaceutical companies are looking beyond manufacturing capacity alone, and named quality certifications, supply chain resilience, advanced R&D capabilities and manufacturing flexibility as key criteria for choosing strategic partners.
What it means for the market
The organizers describe a "Team Taiwan" approach that links the full value chain, from early-stage AI drug discovery to commercial-scale manufacturing. By expanding partnerships in raw material supply, contract manufacturing, co-development and global licensing, Taiwan says it is ready to play a pivotal role in the next generation of global healthcare.
For pharmaceutical companies reviewing their sourcing, the pavilion offers a single point of contact with suppliers across several stages of drug development and production. Whether those pitches turn into agreements is not stated in the announcement.
